Prelude Partners with Lilly to Test KAT6A Degrader in Breast Cancer Combos
PRLD has more than doubled off its 52-week low of $1.15.
Summary
Prelude Therapeutics announced a clinical trial collaboration and supply agreement with Eli Lilly to evaluate its KAT6A selective degrader PRT13722 in combination with Lilly's abemaciclib (Verzenio) and imlunestrant (Inluriyo) in patients with HR+/HER2- breast cancer. The combinations will be added to Prelude's Phase 1 trial, which received FDA clearance in September and is expected to begin enrollment in Q4 2026. Prelude retains full global rights to PRT13722. This partnership validates the program's potential and provides access to standard-of-care agents, potentially accelerating development. The collaboration follows the FDA clearance of the Phase 1 study and builds on preclinical data showing synergy with CDK4/6 inhibitors and endocrine therapies.
At the time of this announcement, PRLD was trading at $3.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $298.5M. The 52-week trading range was $1.15 to $6.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.